Anthos Therapeutics announced the publication of positive results from its AZALEA-TIMI 71 study in the •New England Journal of Medicine•. The study evaluated abelacimab, a Factor XI inhibitor, against rivaroxaban (a standard direct oral anticoagulant or DOAC) in atrial fibrillation patients at moderate-to-high stroke risk. Abelacimab demonstrated a significant reduction in bleeding events across all primary and secondary endpoints.
This news holds substantial implications for atrial fibrillation management. Current anticoagulants effectively reduce stroke risk, but carry a significant bleeding risk, leading to undertreatment and preventable strokes. Abelacimab’s demonstrated ability to significantly reduce bleeding, while potentially maintaining efficacy in stroke prevention, could encourage wider adoption of anticoagulation therapy among eligible patients and physicians. This could translate into fewer strokes and improved patient outcomes, addressing a significant unmet need in cardiovascular care.
The AZALEA-TIMI 71 Phase 2 study, the longest head-to-head study of its kind, showed a 62% reduction in major or clinically relevant non-major bleeding with abelacimab compared to rivaroxaban. Furthermore, major bleeding alone was reduced by 67%, and gastrointestinal bleeding saw an 89% reduction. The study also indicated sustained Factor XI inhibition of 99% with monthly 150mg abelacimab dosing. Previous data presentations from the study also highlighted low periprocedural bleeding rates and similar benefits in patients on antiplatelet therapy.
Abelacimab’s positive results pave the way for its potential emergence as a safer and more convenient anticoagulant option. Pending further research, particularly the ongoing LILAC-TIMI 76 study comparing abelacimab to placebo in stroke prevention, abelacimab could reshape the landscape of atrial fibrillation treatment, improving patient care and potentially reducing the burden of this widespread condition.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
